Jump to page content

Unlike other R&D funding measures, Go-Bio does not require a high degree of concretization at the start of the project. Interested research teams from universities and non-university research institutions can submit their project outlines once a year, by February 15th. The selection and application for the one-year conceptual exploratory phase then takes place in April and May. In this first phase, selected projects can initially hone their exploitation ideas and carry out market and freedom-to-operate (FtO) analyses. 

In a second selection process, successful exploratory projects are given the opportunity to move on to the two-year feasibility phase in order to provide the technical proof of principle. As part of the project implementation, the research results should reach a level of maturity that enables continuation in other established validation, start-up and company cooperation funding programs, such as VIP+, EXIST-Forschungstransfer, KMU-innovativ or GO-Bio next. The overarching goal is the seamless transfer of promising ideas into application.

Our following four teams will enter the exploratory phase in October 2024

- NEUROLITH: Development of a tissue implant for the causal therapy of traumatic spinal cord injury and the resulting paraplegia (under the direction of Dr. med. univ. Jacob Spinnen: Clinic for Trauma and Reconstructive Surgery)

- SIC: Intelligent sensor-based control system for cardiovascular implants using the example of an atrial occluder (under the direction of Dr. med. univ. Markus Reinthaler: Department of Cardiology, Angiology and Intensive Care Medicine)

- KardioDetekt: Wearable biosensor for sweat-based detection and prevention of cardiovascular diseases for patient-specific telemedicine (under the direction of Paul Geus, M.Sc.: Institute for Cardiovascular Computer-Assisted Medicine)

- Mykopoint: Patient-specific point-of-care system for rapid combination therapy of fungal infections (Dipl.-Ing. Michael Lommel, Institute of Cardiovascular Computer-Assisted Medicine)

In addition to expert advice, the projects will each receive €100,000 in funding. Charité BIH Innovation will advise the teams during the exploratory phase on all issues relating to transfer, intellectual property rights and founding. “I am particularly pleased that three of the project managers have already gained a wealth of experience in our BIH funding programs, such as the SPARK BIH program,” says Thomas Gazlig, Head of Charité BIH Innovation. If you have any questions about the funding program, interested applicants can contact our start-up consultant Dr. Bettina Otto (bettina.otto@bih-charite.de).